Compare RPAY & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPAY | EMBC |
|---|---|---|
| Founded | 2006 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.0M | 328.1M |
| IPO Year | 2018 | 2021 |
| Metric | RPAY | EMBC |
|---|---|---|
| Price | $4.35 | $6.73 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 4 |
| Target Price | ★ $6.85 | $4.00 |
| AVG Volume (30 Days) | 322.0K | ★ 836.9K |
| Earning Date | 11-09-2026 | 11-24-2026 |
| Dividend Yield | N/A | ★ 0.58% |
| EPS Growth | N/A | ★ 20.90 |
| EPS | N/A | ★ 1.03 |
| Revenue | ★ $309,261,000.00 | N/A |
| Revenue This Year | $59.12 | N/A |
| Revenue Next Year | $27.40 | $5.59 |
| P/E Ratio | ★ N/A | $6.63 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.30 | $2.77 |
| 52 Week High | $5.25 | $14.91 |
| Indicator | RPAY | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 66.12 | 67.69 |
| Support Level | $3.51 | $3.01 |
| Resistance Level | $4.55 | $9.38 |
| Average True Range (ATR) | 0.15 | 0.28 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 99.14 | 84.15 |
Repay Holdings Corp is a payments technology company. It provides integrated payment processing solutions to industry-oriented vertical markets in which businesses or other organizations have specific transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments. The company generates majority of its revenue from Consumer Payments segment.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.